Ralfinamide
http://dbpedia.org/resource/Ralfinamide an entity of type: Thing
Ralfinamide (INN) (code names NW-1029, FCE-26742A, PNU-0154339E) is a multimodal drug which is under investigation by for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain. It has a relatively complex pharmacology, acting as a mixed voltage-gated sodium channel blocker (including Nav1.7), N-type calcium channel blocker, noncompetitive NMDA receptor antagonist, and monoamine oxidase B inhibitor.
rdf:langString
rdf:langString
Ralfinamide
xsd:integer
44929146
xsd:integer
985900361
rdf:langString
None
xsd:integer
17
xsd:integer
133865
xsd:integer
2107771
xsd:integer
4676525
xsd:integer
1
xsd:integer
19
rdf:langString
N2-{4-[oxy]benzyl}-L-alaninamide
xsd:integer
2
xsd:integer
2
xsd:integer
5745207
rdf:langString
C[C@@H]NCc1cccOCc2ccccc2F
xsd:integer
1
rdf:langString
BHJIBOFHEFDSAU-LBPRGKRZSA-N
xsd:integer
3
rdf:langString
Ralfinamide (INN) (code names NW-1029, FCE-26742A, PNU-0154339E) is a multimodal drug which is under investigation by for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain. It has a relatively complex pharmacology, acting as a mixed voltage-gated sodium channel blocker (including Nav1.7), N-type calcium channel blocker, noncompetitive NMDA receptor antagonist, and monoamine oxidase B inhibitor. It has thus far progressed as far as phase IIb/phase III clinical trials. In 2010 it failed a phase II trial for lower back pain. Encouraging Phase II results have been announced for neuropathic pain.
xsd:nonNegativeInteger
6682
xsd:string
133865-88-0
xsd:string
2107771
xsd:string
3LPF0S0GVV
xsd:string
5745207